Beers SR, Skold A, Dixon CE, Adelson PD. Neurobehavioral Effects of Amantadine After Pediatric Traumatic Brain Injury.
J Head Trauma Rehabil 2005;
20:450-63. [PMID:
16170253 DOI:
10.1097/00001199-200509000-00006]
[Citation(s) in RCA: 54] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE
To investigate the safety and efficacy of a dopamine agonist, amantadine hydrochloride (AMH), in the treatment of neurobehavioral sequelae of pediatric TBI.
PROCEDURES
Age- and severity-matched traumatic brain injury groups, randomized to AMH (n = 17) or usual care (n = 10), completed behavior scales and neuropsychological tests. Effect sizes measured the treatment effect within subjects and between groups. Side effects were tracked over the 12-week study course.
RESULTS
Behavior improved in the AMH group, but only those 2 years or fewer postinjury showed a treatment effect on cognitive tests.
CONCLUSIONS
After traumatic brain injury, a 12-week course of AMH was safe and, according to parent report, improved behavior. AMH may have the potential to improve cognition in more recently injured children.
Collapse